<DOC>
	<DOCNO>NCT01705899</DOCNO>
	<brief_summary>Islet transplantation provide physiologic insulin replacement patient type 1 diabetes without complication associate whole pancreas transplantation . The purpose study achieve insulin-independence patient type 1 diabetes , thereby eliminate need exogenous insulin injection maintain normal glucose level , ameliorate severe hypoglycemia potentially decrease development diabetes-related complication . This study investigate islet transplantation subject preserve renal function subject undergone cadaveric renal transplantation , since latter subject already immunosuppression . This single center , prospective trial islet transplantation subject receive islet alone islet kidney transplant . This phase I study investigate use islet transplantation treatment type 1 diabetes . Subjects eligible islet transplant meet inclusion criterion none exclusion criterion outline protocol . In brief , aim study establish islet transplant program Ohio State University , determine safety islet transplantation islet alone kidney transplant recipient , determine whether islet transplantation reduce frequency severe hypoglycemic event , determine whether novel steroid-free immunosuppressive protocol prevent rejection islet transplant achieve insulin independence one year final islet transplant .</brief_summary>
	<brief_title>Islet Allotransplantation Type 1 Diabetes</brief_title>
	<detailed_description>Hypothesis - Insulin independence ( insulin injection longer need ) achieve subject type 1 diabetes receive islet transplantation use immunosuppressive regimen cyclosporine sirolimus . Amelioration severe hypoglycemia also achieve group . Primary Objective To determine safety islet transplantation islet alone kidney transplant recipient . Safety analyse include : - Incidence , time severity adverse event relationship transplant protocol , islet infusion immunosuppressive medication - Proportion without protocol-related serious adverse event ( SAE ) 1 year - Incidence , type severity infectious complication - Incidence severity procedural-related event , bleed portal vein thrombosis - Incidence severity liver function test elevation - Incidence severity hypoglycemia - Incidence severity creatinine clearance urine microalbumin change - Incidence severity lipid abnormality - Proportion develop donor-specific alloantibody Secondary Objective To determine efficacy islet transplantation islet alone kidney transplant recipient . Efficacy analyse include : - Time insulin independence , define freedom insulin use ( insulin injection need ) 14 consecutive day - Proportion achieve insulin independence time first year - Proportion one year final transplant : - Positive C-peptide ( ≥0.3 ng/ml stimulation ) - Full function graft - Partial function graft - Marginal function graft - Mixed meal stimulate C-peptide &gt; 1.0 ng/ml 6 , 12 month - Proportion acute insulin response glucose ( AIRg ) &gt; 20uU/ml frequently sample intravenous glucose tolerance test ( FSIGT ) 6 12 month - Proportion blood glucose level &lt; 140 mg/dl two hour oral glucose tolerance test ( OGTT ) 6 12 month - Proportion improve QOL 6 12 month compare baseline - Proportion improve hypoglycemia glycemic lability score 6 12 month compare baseline Definition full islet function : - Insulin independence - A1C ≤ 6.5 % - Absence severe hypoglycemic episode - Fasting glucose ≥140 mg/dl le 3 time week - Post-prandial glucose ( 2 hour ) &gt; 180 mg/dl less 4 time week Definition partial islet function : - Insulin requirement le 50 % pre-transplant insulin requirement - C-peptide positive ( ≥0.3 ng/ml stimulation ) - A1C ≤ 6.5 % - No severe hypoglycemia Definition marginal islet function : - C-peptide positive ( ≥0.3 ng/ml stimulation ) - A1C ≤ 7.5 % - No severe hypoglycemia This trial two study group consist N=10 subject type 1 diabetes . One group ( IA ) include subject preserve kidney function . A second group ( IAK ) include subject renal failure secondary diabetes receive prior kidney transplant least 6 month previously stable renal function steroid-free immunosuppressive regimen . Potential study participant recruit Endocrinology Transplant clinic Ohio State University , community physician referral . Those potentially eligible undergo screen evaluation review medical record . If subject remain eligible , he/she enrol islet transplant study place wait list islet transplant . Once transplant becomes available , subject admit hospital undergo transplant procedure . Frequent follow-up visit transplant clinic occur throughout follow year transplant . Subjects closely monitored adverse event insulin requirement . If subject achieve insulin independence , he/she may eligible subsequent transplant . There 10-year enrollment 12-month follow-up last transplant . Since subject may eligible subsequent transplant within 18 month first transplant , total duration may 30 month first transplant subject . The study complete one year last islet transplant . Subjects undergone islet transplant procedure complete post-transplant evaluation one year last transplant consider complete study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>1 . Type 1 diabetes &gt; 5 year 2 . First islet transplant 3 . Demonstrate intensive effort manage diabetes last 6 month ( ≥4 SMBG/day , ≥3 injection insulin/day use pump ≥3 contact diabetes care team last 12 month ) 4 . Metabolic complication : least one following : •Reduced hypoglycemia awareness ( inability sense hypoglycemia blood glucose fall &lt; 54 mg/dl &gt; one hypoglycemic episode last 12 month require outside help explain clear precipitant ) •≥2 severe hypoglycemic event ≥2 hospitalization diabetic ketoacidosis ( DKA ) last year . 5 . Ability provide write informed consent 6 . Age 1865 7 . Specific group 2 : All ( 16 ) renal transplant least 6 month previous 1 . Age &lt; 18 year &gt; 65 year 2 . Inability provide inform consent 3 . Body Mass Index &gt; 29 kg/m2 4 . Insulin requirement &gt; 50 units/day 5 . Stimulated Cpeptide ≥ 0.2 ng/ml 6 . Current panel reactive antiHLA antibody &gt; 20 % 7 . Cardiovascular instability 8 . Previous islet transplant 9 . History malignancy except squamous basal cell skin cancer unless diseasefree &gt; 2 year determine independent oncologist 10 . Active peptic ulcer disease 11 . Condition may interfere absorption medication 12 . Hemoglobin A1C &gt; 12 % 13 . Invasive aspergillus infection within one year 14 . Varicella titer index &lt; 1.0 15 . Rubella titer &lt; 10 IU/ml 16 . Psychiatric disorder 17 . Untreated hyperlipidemia : fasting total cholesterol &gt; 240 mg/dl , low density lipoprotein &gt; 130 mg/dl , triglycerides &gt; 200 mg/dl 18 . Hemoglobin &lt; 10 g/dl female , &lt; 11 g/dl male , white blood cell count &lt; 3,000/µL , platelet count &lt; 150,000/microliter , CD4+ count &lt; 500/microliter 19 . Liver function test abnormality ( value &gt; 1.5 time normal , candidate exclude . If 11.5 time normal , test repeat . If retest value remain normal , candidate exclude ) . 20 . Prostate specific antigen &gt; 4.0 ng/ml 21 . Presence gallstone , liver hemangioma , cirrhosis evidence portal hypertension 22 . Untreated proliferative diabetic retinopathy 23 . Females : positive pregnancy test , intent future pregnancy , subject reproductive age surgically sterile unable unwilling use acceptable method contraception 24 . Female subject breastfeed 25 . Adrenal insufficiency : 8am cortisol &gt; 19 mcg/dl adequate . Values 19 mcg/dl follow AdrenoCorticotropic Hormone stimulation test 26 . Any disease condition require use chronic steroid 27 . Coagulopathy use chronic anticoagulation 28 . Hyperthyroidism unless treat radioactive iodine surgery 29 . Thyroid function test outside normal range 30 . Active alcoholism substance abuse within past six month 31 . History nonadherence . Questionable adherence require agreement enter compliance demonstrate least 3 month 32 . Active infection include hepatitis B C , human immunodeficiency virus positive , positive Mantoux test [ unless previously immunize Bacillus CalmetteGuerin ] , Xray evidence pulmonary infection 33 . Inability reach hospital within 6 hour notification 34 . Failure clear psychological psychiatric screen 35 . Medical condition circumstance investigator find interfere safe completion study Exclusion criterion specific group 1 : 1 . Receipt previous transplant ( exclude pancreas ) 2 . Creatinine clearance &lt; 50 ml/minute female &lt; 60 ml/minute male macroalbuminuria ( &gt; 500 mg/24h ) Exclusion criterion specific group 2 : 1 . Creatinine clearance &lt; 40ml/minute 2 . Renal transplant last 6 month 3 . Current use corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Islet transplant</keyword>
	<keyword>Kidney transplant</keyword>
</DOC>